Nivolumab vs Tofacitinib
Nivolumab vs Tofacitinib: Overview
This comparison examines the pharmacological differences between Nivolumab and Tofacitinib.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Tofacitinib: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.
Pharmacokinetics
Half-life: Nivolumab — 27 days; Tofacitinib — 3.2 hours.
Chemical Properties
Molecular Formula: Tofacitinib — C16H20N6O.
Molecular Weight: Tofacitinib — 312.3700 g/mol.
Type: Nivolumab — Antibody; Tofacitinib — Small molecule.